A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer
Ontology highlight
ABSTRACT: Interventions: control group:Camrelizumab;experimental group 1:Camrelizumab;experimental group:bevacizumab / apatinib
Primary outcome(s): complete pathological response rate
Study Design: Non randomized control
DISEASE(S): Colorectal Cancer
PROVIDER: 2759992 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA